These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10786197)

  • 21. [Topotecan, a recent discovery and prospects for treating tumors of the lung].
    Gridelli C
    Tumori; 1999; 85(6 Suppl 1):S16-22. PubMed ID: 10786196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies].
    Wu DP; Tang XW; Sun AN; Qiu HY; Fu ZZ; Ma R; Ruan CG
    Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):599-601. PubMed ID: 14690573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
    Hochster H; Wadler S; Runowicz C; Liebes L; Cohen H; Wallach R; Sorich J; Taubes B; Speyer J
    J Clin Oncol; 1999 Aug; 17(8):2553-61. PubMed ID: 10561322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
    J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
    Ardizzoni A; Hansen H; Dombernowsky P; Gamucci T; Kaplan S; Postmus P; Giaccone G; Schaefer B; Wanders J; Verweij J
    J Clin Oncol; 1997 May; 15(5):2090-6. PubMed ID: 9164222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topotecan in the treatment of recurrent small cell lung cancer: an update.
    Ardizzoni A
    Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Topoisomerase inhibitors developing in Japan].
    Furue H
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
    Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
    Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topoisomerase I interactive drugs in children with cancer.
    Stewart CF; Zamboni WC; Crom WR; Gajjar A; Heideman RL; Furman WL; Meyer WH; Houghton PJ; Pratt CB
    Invest New Drugs; 1996; 14(1):37-47. PubMed ID: 8880392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
    Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
    J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymoquinone from Nigella sativa Seeds Promotes the Antitumor Activity of Noncytotoxic Doses of Topotecan in Human Colorectal Cancer Cells in Vitro.
    Khalife R; Hodroj MH; Fakhoury R; Rizk S
    Planta Med; 2016 Mar; 82(4):312-21. PubMed ID: 26848703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
    Seiden MV; Muggia F; Astrow A; Matulonis U; Campos S; Roche M; Sivret J; Rusk J; Barrett E
    Gynecol Oncol; 2004 Apr; 93(1):229-32. PubMed ID: 15047241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.